Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus

Annals of Family Medicine

Volumn 8, Issue 6, 2010, Pages 542-549

  Lee, Nancy J ^a   Norris, Susan L ^a   Thakurta, Sujata ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Amylin; Diabetes mellitus; Pramlintide; Systematic review

Indexed keywords

AMYLIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PRAMLINTIDE;

BIBLIOGRAPHIC DATABASE; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITATIVE RESEARCH; REVIEW;

BLOOD GLUCOSE; DATABASES, BIBLIOGRAPHIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLET AMYLOID POLYPEPTIDE; QUALITATIVE RESEARCH;

EID: 78449294264     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1174     Document Type: Article

References (29)

1. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005-2012.
2. Weyer C, Fineman MS, Strobel S, et al. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005;62(8):816-822.
3. Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J, eds. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews. CRD report number 4 (2nd ed). York: NHS Centre for Reviews and Dissemniation (CRD); 2001.
4. Harris RP, Helfand M, Woolf SH, et al.; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3)(Suppl):21-35.
5. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189-2195.
6. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-790.
7. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204-1212.
8. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002;4(1):51-61.
9. Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(11):2794-2799.
10. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724-730.
11. Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009;32(9):1577-1582.
12. Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associate'd with glucose variability in type 1 diabetes. Diabetes Technol Ther. 2008;10(5):391-396.
13. Marrero DG, Crean J, Zhang B, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007;30(2):210-216.
14. Peyrot M, Rubin RR. How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference. Diabetes Care. 2009;32(8):1411-1417.
15. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12(4):661-668.
16. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003;5(6):408-414.
17. Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C. Effect of pramlintide on A1c and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003;52(12):1638-1642.
18. Ratner R, Whitehouse F, Fineman MS, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005;113(4):199-204.
19. US Food and Drug Administration. Pramlintide Medical Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%20Injection_medr.PDF. Accessed Dec 15, 2009.
20. US Food and Drug Administration. Pramlintide Statistical Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%20Injection_statr.PDF. Accessed December 15, 2009.
21. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977-2983.
22. Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9(2):191-199.
23. Peyrot M, Rubin RR, Polonsky WH. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther. 2008;10(6):461-466.
24. Moher D, Pham B, Lawson ML, Klassen TP. The inclusion of reports of randomised trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7(41):1-90.
25. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol. 2005;58(9):894-901.
26. Terrin N, Schmid CH, Lau J, Olkin I. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003;22(13):2113-2126.
27. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(7):921-928.
28. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-1170.
29. Chan A-W, Hro'bjartsson A, Haahr HT, Gotzsche PC, Altman DG. Empirical evidence of selective reporting of outcomes in randomized controlled trials. JAMA. 2004;291(20):2457-2465.